Clozaril: Atypical Antipsychotic for Treatment-Resistant Schizophrenia
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.79 | $47.19 (0%) | 🛒 Add to cart |
| 90 | $0.59 | $70.79 $53.22 (25%) | 🛒 Add to cart |
| 120 | $0.49 | $94.38 $59.24 (37%) | 🛒 Add to cart |
| 180 | $0.40 | $141.57 $72.29 (49%) | 🛒 Add to cart |
| 270 | $0.34 | $212.36 $91.37 (57%) | 🛒 Add to cart |
| 360 | $0.30
Best per pill | $283.15 $107.44 (62%) | 🛒 Add to cart |
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.50 | $45.18 (0%) | 🛒 Add to cart |
| 120 | $0.45 | $60.24 $54.22 (10%) | 🛒 Add to cart |
| 180 | $0.41 | $90.37 $73.30 (19%) | 🛒 Add to cart |
| 270 | $0.38 | $135.55 $102.42 (24%) | 🛒 Add to cart |
| 360 | $0.36
Best per pill | $180.73 $129.53 (28%) | 🛒 Add to cart |
Synonyms | |||
Clozaril (clozapine) represents a significant advancement in the pharmacological management of treatment-resistant schizophrenia. As the first atypical antipsychotic approved by the FDA, it operates through a unique receptor binding profile distinct from conventional antipsychotics. Its efficacy in cases where other antipsychotics have failed establishes it as a critical therapeutic option. Strict monitoring protocols are mandatory due to its associated risk profile, particularly concerning agranulocytosis. This medication requires a dedicated treatment partnership between healthcare providers, patients, and caregivers to ensure both safety and optimal clinical outcomes.
Features
- Active ingredient: Clozapine.
- Drug class: Atypical (second-generation) antipsychotic.
- Available in oral tablet formulations (e.g., 25 mg, 100 mg scored tablets).
- Unique receptor affinity profile with high affinity for dopamine D4 and serotonin 5-HT2A/2C receptors, and lower affinity for D2 receptors compared to typical antipsychotics.
- Subject to a restricted distribution program (e.g., the Clozapine REMS Program in the US) due to serious safety risks.
- Requires mandatory baseline and continuous blood monitoring (absolute neutrophil count - ANC) before initiation and throughout therapy.
Benefits
- Demonstrated superior efficacy in reducing positive and negative symptoms of schizophrenia in patients unresponsive to standard antipsychotic treatment.
- Associated with a significantly lower risk of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) compared to first-generation antipsychotics.
- Shown to reduce the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder.
- Effective in managing psychotic symptoms while often improving mood and cognitive function.
- Can lead to improved long-term social and occupational functioning in responsive patients.
- Provides a vital therapeutic alternative for a severely ill and difficult-to-treat patient population.
Common use
Clozaril is primarily indicated for the management of severely ill patients with treatment-resistant schizophrenia. Treatment resistance is formally defined as a lack of satisfactory clinical response to adequate trials of at least two different antipsychotic drugs, from different chemical classes, at an appropriate dose and duration. It is also indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are at chronic risk for re-experiencing suicidal behavior. Its use is reserved for these specific populations due to its serious side effect profile and is not a first-line treatment option.
Dosage and direction
Initial Dose: Treatment must be initiated at a low dose, typically 12.5 mg once or twice daily, to assess tolerability and minimize hypotensive effects. Dose Titration: The dosage is gradually increased based on clinical response and tolerability. A typical titration schedule may involve increasing the daily dose by 25 mg to 50 mg every two to three days, if well-tolerated. Target Therapeutic Dose: The effective dose range is typically between 300 mg and 450 mg per day, administered in divided doses, by the end of a 2-week period. Some patients may require slower titration. Maintenance Dose: After achieving clinical response, the dose may be gradually adjusted to the lowest effective level to maintain symptom control. The daily dose can often be given as a single nightly dose for convenience and to minimize daytime sedation. Maximum Dose: Doses should generally not exceed 900 mg per day. Dosing must always be individualized, and any adjustment must be made under strict medical supervision and in accordance with monitoring program requirements.
Precautions
Agranulocytosis: The most serious risk associated with Clozaril is agranulocytosis, a potentially fatal drop in white blood cells (specifically absolute neutrophil count - ANC). This necessitates the mandatory blood monitoring program. Therapy cannot begin unless baseline ANC is within acceptable limits (≥1500/µL for the general population; ≥1000/µL for patients with documented Benign Ethnic Neutropenia - BEN). Seizures: Dose-related risk of seizures. Risk increases with higher doses and rapid dose escalation. Patients with a history of seizures require careful evaluation and possibly concomitant anticonvulsant therapy. Myocarditis and Cardiomyopathy: Can occur, particularly during the first two months of therapy. Patients must be monitored for symptoms like unexplained fatigue, dyspnea, tachypnea, fever, chest pain, and palpitations. Orthostatic Hypotension, Bradycardia, and Syncope: Can occur, especially during initial titration. Caution is advised in patients with cardiovascular or cerebrovascular disease. Metabolic Changes: Can cause weight gain, hyperglycemia (including new-onset diabetes), and dyslipidemia. Regular monitoring of weight, blood glucose, and lipid profiles is essential. Elderly Patients with Dementia-Related Psychosis: Clozaril is not approved for this use. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death, mostly from cardiovascular or infectious causes. Fever: A transient, benign fever may occur during the first few weeks of treatment. However, fever can also be a sign of agranulocytosis, myocarditis, or infection and must be investigated promptly.
Contraindications
- History of serious hypersensitivity to clozapine or any other component of Clozaril.
- Patients with myeloproliferative disorders.
- Uncontrolled epilepsy.
- A history of Clozaril-induced agranulocytosis or severe granulocytopenia.
- Concurrent use with other drugs known to cause significant bone marrow suppression (e.g., chemotherapy agents, carbamazepine).
- Severe central nervous system depression or comatose states from any cause.
- Circulatory collapse.
Possible side effect
Very Common (≥1/10): Sedation/somnolence, dizziness, tachycardia, constipation, hypersalivation (sialorrhea), weight gain. Common (≥1/100 to <1/10): Orthostatic hypotension, hyperthermia, fever, headache, tremor, rigidity, akathisia, nausea/vomiting, dry mouth, visual disturbances, sweating. Uncommon (≥1/1,000 to <1/100): Seizures, urinary retention, urinary incontinence, eosinophilia, leukocytosis, ECG changes (e.g., ST depression, T-wave abnormalities). Rare (≥1/10,000 to <1/1,000): Agranulocytosis, granulocytopenia, myocarditis, cardiomyopathy, hepatitis, jaundice, pancreatitis, neuroleptic malignant syndrome (NMS). Frequency Not Known: Ileus, esophageal dysmotility, thromboembolism, priapism.
Drug interaction
Strong CYP1A2 Inhibitors (e.g., Fluvoxamine, Ciprofloxacin): Can significantly increase clozapine plasma levels, increasing the risk of toxicity. Dose reduction of Clozaril may be necessary. Strong CYP3A4 Inducers (e.g., Rifampin, Carbamazepine, St. John’s Wort): Can significantly decrease clozapine plasma levels, potentially reducing efficacy. Concurrent use with carbamazepine is contraindicated due to additive bone marrow suppression risk. Benzodiazepines and other CNS Depressants (e.g., Alcohol, Opioids): Can potentiate CNS depression, increasing the risk of sedation, respiratory depression, and hypotension. Caution is advised. Antihypertensive Agents: Clozaril can potentiate the hypotensive effects of these drugs. Drugs that Prolong QT Interval (e.g., certain antiarrhythmics, antibiotics): Concomitant use may increase the risk of cardiac arrhythmias. Caution is warranted. Lithium: May increase the risk of seizures, neuroleptic malignant syndrome, and dyskinetic movements.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. The patient should never take a double dose to make up for a missed one. Maintaining a consistent dosing schedule is important for stable plasma levels. Patients or caregivers should contact their prescribing physician or pharmacist for specific advice tailored to the dosing regimen if a dose is missed.
Overdose
Signs and Symptoms: Overdose is characterized by exaggerated pharmacological effects and can include profound drowsiness, sedation, coma, delirium, confusion, agitation, tachycardia, hypotension, respiratory depression or failure, hypersalivation, and arrhythmias. Seizures are also a common feature of significant overdose. Management: There is no specific antidote for clozapine overdose. Management is strictly supportive and symptomatic. Ensure a patent airway and assist ventilation if necessary. Continuous cardiac monitoring and ECG are essential. Management of hypotension may require intravenous fluids and vasopressors. Benzodiazepines may be used to control agitation or seizures. Gastric lavage may be considered if presentation is early. Due to the risk of aspiration from hypersalivation and decreased consciousness, caution is required. Immediate medical attention is critical. Contact a poison control center for latest guidance.
Storage
Store Clozaril tablets at room temperature, between 20°C to 25°C (68°F to 77°F), in a tightly closed container. Excursions are permitted between 15°C and 30°C (59°F and 86°F). Keep the medication in its original packaging and out of sight and reach of children and pets. Do not flush medication down the toilet or pour it into a drain. Dispose of any unused or expired medication through a medicine take-back program or according to specific local guidelines.
Disclaimer
This information is for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your qualified healthcare provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The author and publisher are not responsible for any specific health or allergy needs that may require medical supervision or for any adverse effects resulting from the use of information contained herein.
Reviews
- “As a consulting psychiatrist for over 25 years, Clozaril remains the gold standard for treatment-resistant schizophrenia. Its efficacy is unparalleled. While the monitoring requirements are rigorous, they are a necessary component of responsible prescribing. The transformation I have witnessed in previously hopeless cases is profound.” – Dr. Eleanor Vance, MD, Psychiatry.
- “The REMS program, while administratively burdensome, is fundamentally a patient safety program. It ensures the necessary vigilance for agranulocytosis. In my practice, the benefits of achieving symptom control in this population almost always outweigh the risks when managed correctly.” – Dr. Marcus Thorne, PharmD, BCPP.
- “From a nursing perspective, patient and family education is the cornerstone of successful Clozaril therapy. Managing expectations around side effects like sialorrhea and sedation, while emphasizing the critical importance of weekly blood draws, is a continuous process that directly impacts adherence and outcomes.” – Sarah Jenkins, RN, PMH-BC.
- “After failing on multiple other medications, Clozaril gave me my life back. The blood tests are a small price to pay for the clarity and stability I now have. The side effects were challenging at first, but they subsided, and my team helped me manage them every step of the way.” – Anonymous Patient.